|
|
|
| Expression of Ⅲ type fibronectin like inclusion domain 1 protein in esophageal carcinoma and its clinical significance |
| YUAN Qingfeng ZHANG Qi YANG Yunjie |
| Department of Thoracic Srugery, Bazhong Central Hospital, Sichuan Province, Bazhong 636000, China |
|
|
|
Abstract Objective To investigate the expression of Ⅲ type fibronectin like inclusion domain 1 (FNDC1) protein in esophageal carcinoma and its clinical significance. Methods Immunohistochemistry and real-time quantitative PCR were used to detect the expression of FNDC1 in cancer tissues and paracancerous tissues of 93 patients with esophageal cancer who were diagnosed and treated in Bazhong Central Hospital of Sichuan Province from April 2013 to April 2015. The relationship between the expression of FNDC1 and the clinicopathological characteristics in cancer tissues was analyzed. After five years of follow-up, the difference in prognosis of patients with different FNDC1 expression in cancer tissues by survival was analyzed Kaplan-Meier. Results The relative expression level of FNDC1 mRNA in cancer tissues was significantly higher than that in adjacent tissues (P ＜ 0.05); the positive staining of FNDC1 was mainly located in the cytoplasm of tumor cells in cancer tissues, and the positive expression rate of FNDC1 in cancer tissues was significantly higher than that in adjacent tissues (P ＜ 0.05). The expression of FNDC1 protein in cancer tissues was correlated with tumor stage and lymph node metastasis (P ＜ 0.05). Follow-up was 3-60 months, the 5-year overall survival rate of FNDC1 positive patients was significantly lower than that of FNDC1 negative patients (P ＜ 0.05), and the mean survival time of FNDC1 positive patients was significantly shorter than that of FNDC1 negative patients (P ＜ 0.05). Conclusion The expression of FNDC1 is increased in esophageal cancer tissues, and the expression of FNDC1 is related to tumor stage and lymph node metastasis, and may become a marker to judge the survival prognosis of patients with esophageal cancer.
|
|
|
|
|
|
[1] 陈茹，郑荣寿，张思维，等.2015年中国食管癌发病和死亡情况分析[J].中华预防医学杂志，2019，53（11）：1094-1097.
[2] 邹志强，袁耒，胡凤标，等.开放手术与腔镜下根治切除术治疗胸段食管鳞癌的病例对照研究[J].中国胸心血管外科临床杂志，2018，25（1）：78-82.
[3] Hayashi H，Al Mamun A，Sakima M，et al. Activator of G-protein signaling 8 is involved in VEGF-mediated signal processing during angiogenesis [J]. J Cell Sci，2016，129（6）：1210-1222.
[4] Deng AY，Chauvet C，Ménard A. Alterations in Fibronectin Type Ⅲ Domain Containing 1 Protein Gene Are Associated with Hypertension [J]. PLoS One，2016，11（4）：151-169.
[5] Sato M，Hiraoka M，Suzuki H，et al. Protection of cardiomyocytes from the hypoxia-mediated injury by a peptide targeting the activator of G-protein signaling 8 [J]. PLoS One，2014，9（3）：91-98.
[6] Liu YP，Chen WD，Li WN，et al. Overexpression of FNDC1 Relates to Poor Prognosis and Its Knockdown Impairs Cell Invasion and Migration in Gastric Cancer [J]. Technol Cancer Res Treat，2019，18（3）：153-161.
[7] 许瀚，孟祥瑞，周悦，等.FNDC1蛋白在食管癌组织中的表达及干扰FNDC1表达对食管癌细胞生物学行为的影响[J].郑州大学学报：医学版，2020，55（4）：445-450.
[8] 杜君.我国食管癌疾病负担与国家自然科学基金基础研究资助情况的相关性分析[J].中国肿瘤，2019，28（4）：246-251.
[9] Coleman HG，Xie SH，Lagergren J. The Epidemiology of Esophageal Adenocarcinoma [J]. Gastroenterology，2018， 154（2）：390-405.
[10] 姚毓洲，张耿坤，李采霞.常规内镜和色素内镜对早期食管癌,胃癌及癌前病变的诊断价值研究[J].现代消化及介入诊疗，2020，25（5）：124-126.
[11] 陈美燕，王茹，陈章兴.LIMD1经Akt/ERK信号通路抑制食管癌细胞增殖[J].现代消化及介入诊疗，2020，25（1）：64-66，72.
[12] 侯小霞，常志伟，秦艳茹.食管癌靶向治疗研究进展[J].中国实用医刊，2018，45（21）：122-125.
[13] Huang FL，Yu SJ. Esophageal cancer：Risk factors，genetic association，and treatment [J]. Asian J Surg，2018， 41（3）：210-215.
[14] 木亚林，岳恺，李明.miR-381-3p靶向特异性蛋白1抑制mTOR/p70s6k信号通路调控食管癌细胞的增殖和凋亡[J].成都医学院学报，2020，10（1）：33-39.
[15] 邓艳华.个体化护理在胸腔镜食管癌根治术后康复中的应用研究[J].成都医学院学报，2019，9（4）：498-500.
[16] Xiao Y，Wei R，Yuan Z，et al. Rutin suppresses FNDC1 expression in bone marrow mesenchymal stem cells to inhibit postmenopausal osteoporosis [J]. Am J Transl Res，2019，11（10）：6680-6690.
[17] Jun R，Gengming N，Xin W，et al. Overexpression of FNDC1 in Gastric Cancer and its Prognostic Significance [J]. J Cancer，2018，9（24）：4586-4595.
[18] Sakima M，Hayashi H，Mamun AA，et al. VEGFR-3 signaling is regulated by a G-protein activator，activator of G-protein signaling 8，in lymphatic endothelial cells [J]. Exp Cell Res，2018，368（1）：13-23.
[19] Wuensch T，Wizenty J，Quint J，et al. Expression Analysis of Fibronectin Type Ⅲ Domain-Containing（FNDC） Genes in Inflammatory Bowel Disease and Colorectal Cancer [J]. Gastroenterol Res Pract，2019，20（9）：37-44.
[20] Das DK，Ogunwobi OO. A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer [J]. RNA Dis，2017，4（1）：15-23.
[21] Das DK，Naidoo M，Ilboudo A，et al. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin [J]. Exp Cell Res，2016，348（2）：190-200.
[22] Bagordakis E，Sawazaki-Calone I，Macedo CC，et al. Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures [J]. Tumour Biol，2016，37（7）：9045-9057.
[23] Heckman CA，Holopainen T，Wirzenius M，et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis [J]. Cancer Res，2008，68（12）：4754-4762.
[24] 迟少珍，龚咏雪，阴敏.子宫内膜癌组织的FNDC10水平及临床意义[J].临床肿瘤学杂志，2020，25（2）：156-160.
[25] Sato M，Jiao Q，Honda T，et al. Activator of G protein signaling 8 （AGS8） is required for hypoxia-induced apoptosis of cardiomyocytes：role of G betagamma and connexin 43 （CX43） [J]. J Biol Chem，2009，284（45）：31431-31440.
[26] Reddy RB，Khora SS，Suresh A. Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach [J]. PLoS One，2019，14（7）：218-229.
[27] 傅瑜颖.FNDC1基因在胃腺癌组织中的表达及临床意义[D].合肥：安徽医科大学，2019. |
|
|
|
